Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Lung, Respiratory and Thoracic Cancer

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

J Thorac Oncol.

Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G

doi: 10.1016/j.jtho.2017.05.024.

Genitourinary Cancer

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

Anticancer Res.

Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M

doi: 10.21873/anticanres.11480

Lung, Respiratory and Thoracic Cancer

State of the Art: Advances in Malignant Pleural Mesothelioma in 2017

J Thorac Oncol.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T

doi: 10.1016/j.jtho.2018.02.021.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Lancet Oncol.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup

doi: 10.1016/S1470-2045(18)30765-4.

Progress in the Management of Malignant Pleural Mesothelioma in 2017

J Thorac Oncol.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M0, Yang H, Peikert T

doi: 10.1016/j.jtho.2018.02.021.

Lung, Respiratory and Thoracic Cancer

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

doi: 10.1016/j.jtho.2018.08.007.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

Lancet Respir Med.

Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P

doi: 10.1016/S2213-2600(18)30420-X.

Lung, Respiratory and Thoracic CancerRadio-Oncology

Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting

J Thorac Oncol.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK

doi: 10.1016/j.jtho.2019.08.012.

Lung, Respiratory and Thoracic CancerRadio-Oncology

Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma

Ann Thorac Surg.

Bölükbas S, Biancosino C, Redwan B, Eberlein M

doi: 10.1016/

Related content

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

State of the Art: Advances in Malignant Pleural Mesothelioma in 2017

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Progress in the Management of Malignant Pleural Mesothelioma in 2017

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma